Bengaluru-based online pharmacy startup PlatinumRx is reportedly in discussions to raise approximately $32 million (over ₹300 crore) in a new funding round led by Belgium-based investment firm Sofina Ventures. The proposed transaction could value the healthcare startup between $150 million and $200 million (approximately ₹1,400 crore to ₹1,878 crore), marking a significant increase in its valuation as it expands its presence in India’s online pharmacy market.
The potential fundraise comes nearly a year after PlatinumRx secured $6 million in Series A funding from Stellaris Venture Partners and India Quotient. Founded in 2023, the company focuses on helping consumers access affordable alternatives to prescription medicines, particularly for people managing chronic health conditions. However, the latest funding discussions are ongoing, and the final investment amount, valuation and participation of investors have not been confirmed.
PlatinumRx in Talks to Raise $32 Million From Sofina
According to a report by Inc42, Sofina Ventures is expected to lead PlatinumRx’s proposed $32 million funding round.
The investment could value the Bengaluru-based company at between $150 million and $200 million, depending on the final terms of the transaction.
If completed at the upper end of the reported valuation range, the deal would represent a significant milestone for the relatively young healthcare startup.
The discussions are taking place approximately one year after PlatinumRx raised $6 million in its Series A funding round in September 2025.
The company and Sofina had not responded to Inc42’s queries regarding the proposed transaction at the time of publication.
The participation of existing investors in the new round also remains unclear.
The proposed investment highlights continued investor interest in specialised healthcare platforms that focus on affordability, medicine accessibility and technology-driven distribution.
What Is PlatinumRx and How Does Its Business Model Work?
Founded in 2023 by Ashutosh Pandey and Piyush Kumar, PlatinumRx operates an online pharmacy platform designed to make prescription medicines more affordable.
Its business model focuses on helping customers discover lower-priced alternatives to prescribed branded medicines.
Many medicines available in India are sold under different brand names despite containing the same active pharmaceutical ingredients and strengths. PlatinumRx helps customers identify suitable alternatives with matching compositions, allowing them to compare options and potentially reduce their medication expenses.
The platform primarily targets consumers who require medicines regularly, including people managing chronic conditions.
For patients who need long-term treatment, even relatively small differences in medicine prices can translate into considerable savings over time.
PlatinumRx sources medicines directly from pharmaceutical manufacturers and focuses on building a supply chain that can support affordable pricing and product availability.
According to the company’s website, it has served more than 10 lakh customers.
Its platform also operates across India, with licensed pharmacy facilities in Bengaluru, New Delhi and Mumbai.
PlatinumRx’s Previous Funding History
The proposed $32 million round would follow two earlier funding rounds that helped PlatinumRx establish its business and strengthen its operations.
In April 2024, the startup raised approximately $800,000 in a seed funding round led by India Quotient.
It subsequently secured $6 million in Series A funding in September 2025.
Stellaris Venture Partners and India Quotient backed the Series A round, which was intended to support the company’s expansion plans.
The funding was directed towards strengthening its supply chain, expanding order fulfilment capabilities and building its product and technology teams.
PlatinumRx had also outlined plans to establish five additional fulfilment centres and improve sourcing efficiencies to make affordable substitute medicines more accessible.
The proposed $32 million investment would provide another significant capital infusion as the company looks to expand its operations and compete with established online pharmacy platforms.
PlatinumRx Funding History
| Funding Round | Amount | Lead Investors |
|---|---|---|
| Seed – April 2024 | $800,000 | India Quotient |
| Series A – September 2025 | $6 Million | Stellaris Venture Partners, India Quotient |
| Proposed Round – 2026 | $32 Million | Sofina Ventures (reported) |
The proposed 2026 funding round remains under discussion and has not been confirmed as closed.
Why Is Sofina Interested in India’s Online Pharmacy Market?
Sofina is a Belgium-based investment company with a global investment portfolio spanning consumer businesses, healthcare, education and other sectors.
Its reported interest in PlatinumRx comes amid increasing attention towards technology-driven healthcare businesses in India.
The country’s pharmaceutical market offers opportunities for companies addressing medicine affordability, supply-chain efficiency and access to healthcare products.
Online pharmacies are attempting to capture this opportunity through digital platforms that connect consumers with medicine suppliers and offer convenient home delivery.
PlatinumRx differentiates itself through its focus on lower-cost medicine alternatives rather than competing exclusively on delivery speed.
Its business model could appeal to customers who require recurring prescriptions and are particularly sensitive to long-term healthcare expenses.
For investors, the opportunity lies in building a platform that can generate repeat purchases while improving sourcing efficiency and customer retention.
However, the company will also need to maintain product quality, regulatory compliance and reliable fulfilment operations as it scales.
PlatinumRx Faces Competition From Truemeds and Plazza
India’s online pharmacy market is becoming increasingly competitive as startups and established digital platforms explore different approaches to medicine delivery.
PlatinumRx competes in a segment where affordability and access to substitute medicines are important differentiators.
One of its competitors is Truemeds, which has built its business around offering affordable alternatives to branded medicines.
Truemeds raised $85 million in funding in 2025 to expand its generic medicine delivery business.
Another emerging competitor is Plazza, a Bengaluru-based quick medicine delivery startup.
In July 2026, Plazza raised $15 million in a Series A funding round co-led by Accel, Elevation Capital and Nexus Venture Partners, with participation from existing investors All In Capital and Better Capital.
Unlike PlatinumRx’s affordability-focused model, Plazza emphasises rapid medicine delivery, targeting customers who need medicines quickly.
The competitive landscape reflects two different approaches to online pharmacy growth:
| Company | Business Focus | Recent Funding |
|---|---|---|
| PlatinumRx | Affordable substitute medicines | Proposed $32 Mn |
| Truemeds | Generic and lower-cost medicines | $85 Mn in 2025 |
| Plazza | Quick medicine delivery | $15 Mn in July 2026 |
These companies are competing for a larger share of India’s digital pharmacy market, although their business models and customer propositions differ.
PlatinumRx’s Financial Performance and Growth Challenges
While the proposed funding round could significantly increase PlatinumRx’s valuation, the company’s financial performance will remain important for investors.
According to reported FY25 financial disclosures, Afforis Health Technologies Pvt. Ltd., the entity operating PlatinumRx, generated approximately ₹10.67 crore in operating revenue during the financial year.
The company also reported a net loss of approximately ₹7.28 crore.
These figures indicate that PlatinumRx was still operating at an early growth stage in FY25, with considerable investment required to expand its business.
The company must now demonstrate that increasing customer numbers and order volumes can translate into stronger revenue, improved margins and a more sustainable financial model.
Expanding fulfilment infrastructure, improving medicine sourcing and controlling customer acquisition costs will be important to achieving that objective.
The proposed investment could provide the financial resources needed to accelerate these initiatives.
The Bigger Picture
PlatinumRx’s proposed fundraise reflects growing investor interest in India’s healthcare technology and online pharmacy sectors.
Unlike quick-commerce platforms that primarily compete on delivery speed, specialised pharmacy startups are building businesses around affordability, medicine availability and recurring customer requirements.
PlatinumRx’s focus on lower-cost substitutes addresses an important challenge in India’s healthcare system, where long-term medication expenses can create financial pressure for households.
The company’s reported discussions with Sofina also indicate that international investors continue to see opportunities in India’s digital healthcare market.
However, a higher valuation alone will not guarantee long-term success. The startup will need to demonstrate strong customer retention, efficient operations, regulatory compliance and a clear path towards profitability.
Looking Ahead
If the proposed $32 million funding round closes, PlatinumRx could use the additional capital to strengthen its supply chain, establish more fulfilment centres and expand its technology infrastructure. The investment could also help the company reach more customers seeking affordable prescription medicines across India. However, the final funding amount, valuation and investor participation remain subject to ongoing discussions.
For India’s online pharmacy industry, PlatinumRx’s proposed investment highlights the growing importance of affordability as a competitive advantage. With Truemeds, Plazza and other digital healthcare companies expanding their operations, the next phase of competition will likely focus on pricing, medicine availability, customer trust and operational efficiency.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
